Roche Holding has one of the most promising treatments for Alzheimer’s in clinical trials. The drug is several years away ...

An Alzheimer’s drug from Roche cleared a protein that’s a hallmark of the disease from patients’ brains, suggesting the drug ...

The transaction, seen as a vote of confidence, has put the focus on other drug firms testing similar barrier-bridging ...

This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are ...

An experimental Alzheimer’s therapy from Roche successfully cleared a protein that’s a hallmark of the disease from patients’ ...

Roche put forward new data on two of its upcoming, non-invasive blood tests designed to help rule out a diagnosis of ...

Roche has returned the rights to UCB’s anti-tau antibody bepranemab, walking away from a $120 million bet on the Alzheimer’s ...

In an investor presentation, executives hinted at the possibility of seeking an accelerated approval of trontinemab if it can ...

Roche drops a third Alzheimer’s candidate this year, terminating a partnership with UCB just four years after agreeing to ...

New data highlight the potential of the Roche Elecsys® Amyloid Plasma Panel and Elecsys ptau181 for ruling out Alzheimer’s ...

An elderly patient died in a clinical study of Roche Holding AG’s experimental treatment for Alzheimer’s disease, prompting changes to the trial design, although the company said overall ...

Rather than applying a diagnostic label of Alzheimer's disease, we advocate for this being a state of risk." Feldman reported relationships with Annovis, Vivoryon, AC Immune, Biohaven, LuMind ...